Sanofi reported Q3 total sales of 14.4 billion euros, up 14.3%, with new launches contributing approximately 2.2 billion euros, up 19.2%. Dupixen sales reached 5.7 billion euros, while the pipeline comprised 61 development projects and 36 new molecules.
SNY · Sanofi
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Sanofi reported Q3 2026 net sales of €14,444 million, up 14.3% at CER, and business EPS of €3.55, up 19.6% at CER. It raised 2026 guidance: sales growth is now expected at a low-teens percentage at CER.
Sanofi broke ground on a new insulin manufacturing facility in Frankfurt, Germany, with a 36,000-square-meter footprint and full insulin active pharmaceutical ingredient production planned for 2032 once fully licensed.
Sanofi and Regeneron expanded their alliance to co-develop four long-acting antibodies, including REGN20423. Regeneron will receive $1 billion upfront and up to an additional $7 billion in milestones; the companies will share development and commercialization costs and split profits 50:50.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNY
this stock
Sanofi
|
$113.15B | -2.8% | — | — | 0.5% |
|
LLY
ELI LILLY & Co
|
$1.30T | +28.7% | +44.7% | 44.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$656.47B | +31.8% | +6.0% | 41.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$505.56B | +25.2% | +8.6% | 49.2 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$339.66B | +30.9% | +1.3% | 142.0 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 30, 2026
- This year
- 39
Sanofi reported Q3 2026 net sales of €14,444 million, up 14.3% at CER, and business EPS of €3.55, up 19.6% at CER. It raised 2026 guidance: sales growth is now expected at a low-teens percentage at CER.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNY | -2.7% | +15.0% | +7.9% | +6.3% | -2.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +1.2% | +20.6% | +11.4% | +9.7% | -9.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.